ReviewFrontiers in immunology2026
Taxonomy, carcinogenic mechanisms, and advanced molecular diagnosis of Fusobacterium nucleatum in colorectal cancer: from bench to clinical practice.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusobacterium nucleatum (Fn) is recognized as a novel oncogenic organism closely correlated with colorectal cancer (CRC). Fn can induce gut dysbiosis and promote tumorigenesis through various mechanisms, including activation of oncogenic signaling, modulation of the immune microenvironment, metabolic reprogramming, and epigenetic regulation. Although recent technological breakthroughs have yielded high-resolution Fn detection indicators, clinical translation remains compromised by subspecies heterogeneity, emerging taxonomic updates, and non-standardization of diagnostic platforms. This review integrates recent developments regarding Fn pathogenic mechanisms and taxonomic identification in CRC, including genetic heterogeneity analysis at the species and subspecies levels, elucidation of multi-dimensional oncogenic molecular mechanisms, and application of high-resolution detection technologies. Special focus is placed on advancing these findings toward early noninvasive diagnostic markers. Additionally, we discuss the limitations of current studies, technical bottlenecks, and potential directions for future research to pave the way for standardized clinical screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.